Pharmacological Properties, Central Nervous System Effects, and Potential Therapeutic Applications of Atipamezole, a Selective α2‐Adrenoceptor Antagonist
Open accessThe DOI matches its Crossref record.
Abstract
Atipamezole is an α 2‐adrenoceptor antagonist with an imidazole structure. Receptor binding studies indicate that its affinity for α 2‐adrenoceptors and its α 2/α 1 selectivity ratio are considerably higher than those of yohimbine, the prototype α 2‐adrenoceptor antagonist. Atipamezole is not selective for subtypes of α 2‐adrenoceptors. Unlike many other α 2‐adrenoceptor antagonists, it has negligible affinity for 5‐HT 1A and I 2 bindings sites. Atipamezole is rapidly absorbed and distributed from the periphery to the central nervous system. In humans, atipamezole at doses up to 30 mg/subject produced no cardiovascular or subjective side effects, while at a high dose (100 mg/subject) it produced subjective symptoms, such as motor restlessness, and an increase in blood pressure. Atipamezole rapidly reverses sedation/anesthesia induced by α 2‐adrenoceptor agonists. Due to this property, atipamezole is commonly used by veterinarians to awaken animals from sedation/anesthesia induced by α 2‐adrenoceptor agonists alone or in combination with various anesthetics. Atipamezole increased sexual activity in rats and monkeys. In animals with sustained nociception, atipamezole increased pain‐related responses by blocking the noradrenergic feedback inhibition of pain. In tests assessing cognitive functions, atipamezole at low doses has beneficial effects on alertness, selective attention, planning, learning, and recall in experimental animals, but not necessarily on short‐term working memory. At higher doses atipamezole impaired performance in tests of cognitive functions, probably due to noradrenergic overactivity. Recent experimental animal studies suggest that atipamezole might have beneficial effects in the recovery from brain damage and might potentiate the anti‐Parkinsonian effects of dopaminergic drugs. In phase I studies atipamezole has been well tolerated by human subjects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Millan, M. J., Agid, Y., Brüne, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., Connor, R., Davis, S., Deakin, B., DeRubeis, R. J., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3628 · Cited by 1,292
Pertovaara, A. (2006) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.08.001 · Cited by 597
Self-citationGaba, M., & Mohan, C. (2016) · Medicinal Chemistry Research · doi:10.1007/s00044-015-1495-5 · Cited by 366
Optoactivation of Locus Ceruleus Neurons Evokes Bidirectional Changes in Thermal Nociception in Rats
Hickey, L., Li, Y., Fyson, S. J., Watson, T. C., Perrins, R., Hewinson, J., Teschemacher, A. G., Furue, H., Lumb, B. M., & Pickering, A. E. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.4835-13.2014 · Cited by 169
Bari, A., & Robbins, T. W. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3141-6 · Cited by 105
Metadata
- Authors
- Pertovaara, A., Haapalinna, A., Sirviö, J., & Virtanen, R.
- Venue
- CNS Drug Reviews
- Publisher
- Wiley
- Published
- 2005-09
- Volume
- 11
- Issue
- 3
- Pages
- 273-288
- ISSN
- 1080-563X (ISSN-L)
- 1527-3458
- OpenAlex
- W2062822713
- Cited by
- 112
- References
- 0
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological Properties, Central Nervous System Effects, and Potential Therapeutic Applications of Atipamezole, a Selective α2‐Adrenoceptor Antagonist. https://app.cochat.ai/papers/10.1111/j.1527-3458.2005.tb00047.x
- The paper
- Pertovaara, A., Haapalinna, A., Sirviö, J., & Virtanen, R. (2005). Pharmacological Properties, Central Nervous System Effects, and Potential Therapeutic Applications of Atipamezole, a Selective α2‐Adrenoceptor Antagonist. CNS Drug Reviews. https://doi.org/10.1111/j.1527-3458.2005.tb00047.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.